Judit Anido

SpainNuage Therapeutics

CEO & co-founder of Nuage Therapeutics, a Barcelona based spin off from the Institute of Biomedical
Research (IRB) that exploits chemical biology and biomolecular condensation to develop potent and
selective therapeutic agents targeting proteins with disordered regions for challenging indications to
improve patient’s life.
Previously, CEO of CataloniaBio & HealthTech until the end of 2021, the organization that represents
companies in the biomedicine and health sector in Catalonia comprising almost 200 member companies
and knowledge stakeholders that are leaders in research, development (R&D) and innovation. Anido
joins the board of CataloniaBio & HealthTech in 2018 and was the first woman president of the institution.
She was also co-founder of Mosaic Biomedicals, a biotech company spin off from VHIO (Vall d’Hebron
Institute of Oncology) based in Barcelona and dedicated to the development of innovative drugs for
cancer treatment. She led the growth of Mosaic as CEO from 2012 until its merger with the Canadian
company Northern Biologics in 2016, when she assumed the general direction of Mosaic and became
Vice-President of Operations and Corporate Affairs at Northern. In 2020 the assets of the companies
were successfully acquired by Boehringer Ingelheim and AstraZeneca.
PhD in Biology from the University of Barcelona and an MBA from Duke University (United States) with
Certification in Health Sector Management and specialization in Entrepreneurship and Innovation. Anido
accumulates over 10 years experience in cancer research at VHIO and was Associate at the Pipeline
and Portfolio Planning Team at Genentech (Roche Group) in San Francisco.
She has been awarded with the Premi FemTalent 2018, promoted by the Barcelona City Council. She
has also received competitive grants from the Spanish Association Against Cancer (AECC in Spanish),
Rafael del Pino Foundation, Duke University and Caja Madrid Foundation.

Scroll to Top
  • No products in the cart.